Edasalonexent in Development for the Treatment of Duchenne: Information on Three Clinical Trials

Join to learn about edasalonexent, a novel oral NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy, regardless of mutation type.

This webinar will include:

  • An update on the currently enrolling global Phase 3 PolarisDMD trial
  • An introduction to the open-label extension GalaxyDMD trial
  • Results from the Phase 2 MoveDMD trial

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.